Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
CAPSULE
**Dosage and Administration** Adults and children over 14 years - Oral, 500mg initially, followed by 250mg every 6 hours as needed. Dysmenorrhoea - Oral, 500mg three times a day. Note: It is recommended that mefenamic acid should not be used for more than 7 days at a time.
ORAL
Medical Information
**Indications** It is indicated for the relief of moderate pain when therapy will not exceed one week. It is also indicated for the treatment of primary dysmenorrhoea.
**Contraindication** - Avoid in patients with peptic ulceration or inflammatory bowel disease. - Not recommended for children under 14 years of age, women during pregnancy and lactation, and patients know to be hypersensitive to the drug.
M01AG01
mefenamic acid
Manufacturer Information
JOYSON PTE. LTD.
PRIME PHARMACEUTICAL SDN BHD
Active Ingredients
Documents
Package Inserts
Melgesic PI.pdf
Approved: April 6, 2022